The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCLIN.L Share News (CLIN)

  • There is currently no data for CLIN

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

AIM WINNERS & LOSERS: Kibo invests in Eqtec project; Clinigen falls

Thu, 16th Sep 2021 10:55

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Thursday.

----------

AIM - WINNERS

----------

Galileo Resources PLC, up 20% at 1.32 pence, 12-month range 0.61p-2.80p. The miner, with projects in Botswana, Zambia and South Africa, says all conditions for licence sale agreement with ASX-listed Sandfire Resources Ltd have been met. Completion of deal set for September 22. The deal, first announced in January, will see Sandfire pay USD1.5 million in cash for nine Kalahari copper belt licences.

----------

Kibo Energy PLC, up 16% at 0.26 pence, 12-month range 0.16p-0.56p. The Africa- and UK-focused energy company will acquire just under a 55% stake in the proposed Billingham waste gasification and power plant in Teesside, UK. Fellow AIM listing Eqtec PLC will retain just under over a 45% stake. Kibo's initial funding contribution will amount to GBP3 million. Eqtec shares were 2.4% lower.

----------

AIM - LOSERS

----------

Clinigen Group PLC, down 9.7% at 632.14 pence, 12-month range 554.00p-891.79p. Staffordshire-based pharmaceuticals and services provider lowers its earnings before interest, tax, depreciation and amortisation growth outlook for the new financial year. It now expects Ebitda growth between 5% and 10%. Clinigen anticipates lower sales of the Erwinase cancer treatment. Double-digit growth was previously expected. In the year ended June 30, revenue rose 12% to GBP523.6 million from GBP466.7 million. Pretax profit more than doubled to GBP51.8 million from GBP23.2 million.

----------

By Eric Cunha; ericcunha@alliancenews.com

Copyright 2021 Alliance News Limited. All Rights Reserved.

More News
10 Oct 2019 10:50

Clinigen Inks Partnership To Sell Tumor Treatment Azedra Outside US

Clinigen Inks Partnership To Sell Tumor Treatment Azedra Outside US

Read more
3 Oct 2019 09:34

BROKER RATINGS SUMMARY: Peel Hunt Raises Flutter Entertainment To Hold

BROKER RATINGS SUMMARY: Peel Hunt Raises Flutter Entertainment To Hold

Read more
30 Sep 2019 09:55

BROKER RATINGS SUMMARY: Barclays Cuts Whitbread And Raises SSE

BROKER RATINGS SUMMARY: Barclays Cuts Whitbread And Raises SSE

Read more
19 Sep 2019 13:29

Thursday broker round-up

(Sharecast News) - Ferguson: RBC Capital Markets downgrades to underperform with a target price of 5,100p.

Read more
19 Sep 2019 10:36

Clinigen Profit Drops On One-Off Costs, Despite Strong Revenue Growth

(Alliance News) - Clinigen Group PLC said Thursday annual profit dropped sharply on higher amortisation costs on acquired intangibles and acquisition expenses, despite strong revenue the financial

Read more
12 Sep 2019 16:21

UK Earnings, Trading Statements Calendar - Next 7 Days

Friday 13 September  JD WetherspoonFull Year ResultsSthreeQ3 Enterprise Investment

Read more
16 Jul 2019 10:04

Clinigen Expects Increased Annual Profit On Strong Acquisitions

(Alliance News) - Clinigen Group PLC said Thursday it expects to see a double-digit rise in profit and revenue for its recently ended financial year, driven by contributions from the year to the a

Read more
16 May 2019 06:45

CORRECT: Clinigen Retakes Ethyol And Totect US Commercial Rights

(Correcting the headline to clarify that Clinigen already had the products in its portfolio).LONDON (Alliance News) - Clinigen Group PLC on Wednesday said it has agreed to retake the US to

Read more
15 May 2019 12:43

Clinigen to take back US rights to cancer drugs

(Sharecast News) - Aim's Clinigen Group is taking back control of two oncology drugs from US partner Cumberland Pharmaceuticals.

Read more
2 Apr 2019 10:57

Clinigen monopolises global rights for skin cancer treatment

(Sharecast News) - Clinigen now owns the global rights to Proleukin after having acquired the US rights to the treatment on Tuesday following US anti-trust clearance.

Read more
27 Feb 2019 10:23

Clinigen earnings grow following CSM and iQone acquisitions

(Sharecast News) - Specialty pharmaceuticals group Clinigen saw strong earnings and cash flow growth in the first half of its trading year following a period of transformative acquisitions.

Read more
27 Feb 2019 08:55

Clinigen Group Reports "Good" Interim Performance As Revenue Rises

LONDON (Alliance News) - Clinigen Group PLC on Wednesday described its interim performance as "good", with revenue rising 24%, but profit did fall on the prior year.For the six to

Read more
20 Feb 2019 16:10

UK Earnings, Trading Statements Calendar - Next 7 Days

Thursday 21 February BAE SystemsFull Year ResultsRELXFull Year Year AmericanFull

Read more
20 Feb 2019 13:19

Wednesday broker round-up

(Sharecast News) - Ocado: Peel Hunt downgrades to hold with a target price of 110p.

Read more
13 Feb 2019 12:50

Wednesday broker round-up

(Sharecast News) - Workspace Group: Berenberg downgrades to hold with a target price of 900p.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.